-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Spruce Biosciences at Buy, Announces Price Target of $220

Benzinga·12/22/2025 11:31:34
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $220.